Bruce A. Goldsmith

Bruce A. Goldsmith, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Allos Therapeutics Inc and Passage BIO, Inc. Between 20 October 2010 and 21 March 2022, the trades on record add up to 15 filings.

Both buying and selling appear: 3 purchases worth €68k, against 8 sales worth €34k. Taken together, the purchases exceed the sales by €34k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 3 share grants. Since January 2022: 1 purchase and no sales on the market.

A typical purchase (the median) is worth €21k. On 2 out of 3 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The latest filing, published on 23 March 2022, reports an open-market purchase of €29k in Passage BIO, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.